PD-1 combination therapy with IL-2 modifies CD8⁺ T cell exhaustion program

Area of Science:

• Immunology
• Virology
• T cell biology

Background:

• Combination therapy with PD-1 blockade and IL-2 is effective against chronic lymphocytic choriomeningitis virus.
• Understanding the synergistic mechanisms is crucial for optimizing cancer immunotherapies.

Purpose of the Study:

• To elucidate the underlying mechanisms of synergy between PD-1 blockade and IL-2 therapy.
• To investigate how this combination therapy impacts T cell differentiation and function.

Main Methods:

• Analysis of PD-1+TCF1+ stem-like CD8+ T cell differentiation programs.
• Assessment of transcriptional and epigenetic changes in effector CD8+ T cells.
• Investigation of IL-2 receptor (CD25, CD122, CD132) expression and function.
• Utilizing CD25 blocking antibodies and mutated IL-2 to probe CD25's role.

Main Results:

• PD-1 + IL-2 combination therapy generates superior effector CD8+ T cells, unlike PD-1 monotherapy.
• Stem-like CD8+ T cells are not terminally exhausted and can be redirected by IL-2.
• IL-2-induced synergy relies on IL-2 binding to CD25, enhancing the IL-2 receptor complex.
• Blocking CD25 or using CD25-nonbinding IL-2 abrogates the synergistic effects.

Conclusions:

• IL-2 synergizes with PD-1 blockade by altering the differentiation of stem-like CD8+ T cells into highly functional effectors.
• CD25 engagement by IL-2 is critical for this synergy, highlighting a key target for immunotherapy.
• These findings provide a mechanistic basis for the efficacy of PD-1 + IL-2 combination therapy and inform its application in cancer treatment.